Liver tumor growth in the HBx/c-Myc mouse model as a function of sorafenib showed, as in Huh7 xenografts (Fig. 3C) and similar to what is observed in HCC patients, reduction of tumor growth rate, without significant tumor regression (Fig. 3D). Here, MYC is linked to neoplasm.